Sutro Biopharma Q3 EPS $(1.90) Beats $(1.91) Estimate, Sales $9.100M Miss $10.342M Estimate
Benzinga Newsdesk 6 days ago
NewsEarningsEarnings BeatsEarnings Misses
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(1.91) by 0.52 percent. This is a 71.64 percent increase over losses of $(6.70) per share from
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(1.91) by 0.52 percent. This is a 71.64 percent increase over losses of $(6.70) per share from the same period last year. The company reported quarterly sales of $9.100 million which missed the analyst consensus estimate of $10.342 million by 12.01 percent. This is a 6.12 percent decrease over sales of $9.693 million the same period last year.
